Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development. Medigene at a glance: - 1994: founded as a Munich Gene Center spin-off - 2000: IPO, listed on the Frankfurt Stock Exchange - 2001: acquisition of the US biotechnology company NeuroVir - 2004: Acquisition of products and technology of Munich Biotech AG - 2006: Acquisition of the British biotechnology company Avidex Limited - 2014: Acquisition of Trianta Immunotherapies GmbH - 2015: Medigene initiated first proprietary DC vaccine clinical trial - 2016: Medigene’s DC trial entered phase II - 2016: Medigene announced collaboration on first clinical TCR-T trial in Germany - 2016: Medigene signed development partnership to develop and characterize new TCR-Ts for bluebird bio Inc. USA - 2018: Start of the first, own clinical TCR-T trial with MDG1011 - 2018: Expansion of the bluebird bio partnership - 2019: Medigene signed research and development partnership for innovative cellular therapies in Asia with Cytovant/Roivant - Focus on T-cell-directed immunotherapies - T cell receptor-modified T cell (TCR-T)-therapy MDG1011 for indications with high unmet medical need like AML, MM and MDS in clinical Phase I/II trial - Dendritic cell vaccines (DCs) in ongoing clinical phase I/II trial - Over 100 employees with expertise in immunotherapy and pharmaceutical development - Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California For further information please see our press releases, have a look at our annual and quarterly reports, or contact us by phone or e-mail.